Leerink Partnrs Comments on AbbVie's Q2 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of AbbVie in a research report issued to clients and investors on Monday, April 28th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $3.24 per share for the quarter, up from their prior forecast of $3.06. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie's Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.33 EPS, FY2026 earnings at $14.01 EPS, FY2028 earnings at $17.67 EPS and FY2029 earnings at $19.05 EPS.

ABBV has been the subject of a number of other reports. The Goldman Sachs Group restated a "neutral" rating and set a $194.00 price objective on shares of AbbVie in a research note on Tuesday, April 8th. UBS Group boosted their target price on AbbVie from $181.00 to $190.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Bank of America boosted their price objective on AbbVie from $200.00 to $223.00 and gave the company a "neutral" rating in a research report on Tuesday, March 4th. Morgan Stanley boosted their price objective on shares of AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday. Finally, Wells Fargo & Company increased their price target on shares of AbbVie from $210.00 to $240.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $211.41.

AbbVie Trading Up 2.7 %

ABBV stock traded up $5.28 on Wednesday, hitting $198.62. 6,424,665 shares of the company were exchanged, compared to its average volume of 6,081,065. The business's fifty day moving average is $196.25 and its two-hundred day moving average is $187.20. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66. The stock has a market capitalization of $351.35 billion, a price-to-earnings ratio of 82.76, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The firm had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the business posted $2.31 earnings per share. The business's quarterly revenue was up 8.4% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ABBV. Howard Capital Management Group LLC grew its holdings in shares of AbbVie by 20.3% during the 3rd quarter. Howard Capital Management Group LLC now owns 2,012 shares of the company's stock valued at $397,000 after purchasing an additional 339 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in AbbVie by 12.3% in the third quarter. Principal Financial Group Inc. now owns 2,487,363 shares of the company's stock worth $491,204,000 after acquiring an additional 273,078 shares in the last quarter. Westside Investment Management Inc. increased its stake in AbbVie by 1.0% during the 3rd quarter. Westside Investment Management Inc. now owns 17,296 shares of the company's stock valued at $3,403,000 after purchasing an additional 171 shares in the last quarter. Morse Asset Management Inc grew its holdings in shares of AbbVie by 2.4% during the third quarter. Morse Asset Management Inc now owns 7,563 shares of the company's stock valued at $1,494,000 after buying an additional 175 shares during the last quarter. Finally, Aldebaran Financial Inc. bought a new stake in shares of AbbVie during the third quarter valued at approximately $466,000. Hedge funds and other institutional investors own 70.23% of the company's stock.

Insider Activity at AbbVie

In other AbbVie news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the completion of the transaction, the executive vice president now owns 53,234 shares in the company, valued at $11,183,398.72. This trade represents a 52.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 5,778 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the transaction, the executive vice president now directly owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,471 shares of company stock worth $23,426,451 in the last quarter. 0.25% of the stock is owned by insiders.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.30%. The ex-dividend date is Tuesday, April 15th. AbbVie's payout ratio is 279.15%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.